LT3293201T - Adenoviruso ir kontrolinio taško inhibitoriaus derinys vėžio gydymui - Google Patents

Adenoviruso ir kontrolinio taško inhibitoriaus derinys vėžio gydymui

Info

Publication number
LT3293201T
LT3293201T LTEP16188301.2T LT16188301T LT3293201T LT 3293201 T LT3293201 T LT 3293201T LT 16188301 T LT16188301 T LT 16188301T LT 3293201 T LT3293201 T LT 3293201T
Authority
LT
Lithuania
Prior art keywords
treating cancer
checkpoint inhibitors
adenovirus
combining
combining adenovirus
Prior art date
Application number
LTEP16188301.2T
Other languages
English (en)
Lithuanian (lt)
Inventor
Tuuli RANKI
Sari Pesonen
Magnus JÄDERBERG
Elina HAAVISTO
Lukasz KURYK
Antti Vuolanto
Original Assignee
Targovax Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targovax Oy filed Critical Targovax Oy
Publication of LT3293201T publication Critical patent/LT3293201T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
LTEP16188301.2T 2016-09-12 2016-09-12 Adenoviruso ir kontrolinio taško inhibitoriaus derinys vėžio gydymui LT3293201T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16188301.2A EP3293201B1 (en) 2016-09-12 2016-09-12 Combining adenovirus and checkpoint inhibitors for treating cancer

Publications (1)

Publication Number Publication Date
LT3293201T true LT3293201T (lt) 2021-03-25

Family

ID=56926041

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16188301.2T LT3293201T (lt) 2016-09-12 2016-09-12 Adenoviruso ir kontrolinio taško inhibitoriaus derinys vėžio gydymui

Country Status (14)

Country Link
US (2) US10940203B2 (enExample)
EP (2) EP3783032A1 (enExample)
JP (2) JP7146739B2 (enExample)
CN (1) CN109715664A (enExample)
AU (1) AU2017324482A1 (enExample)
DK (1) DK3293201T3 (enExample)
ES (1) ES2845690T3 (enExample)
HR (1) HRP20210133T1 (enExample)
HU (1) HUE053236T2 (enExample)
LT (1) LT3293201T (enExample)
PL (1) PL3293201T3 (enExample)
PT (1) PT3293201T (enExample)
SI (1) SI3293201T1 (enExample)
WO (1) WO2018046803A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10350275B2 (en) * 2013-09-21 2019-07-16 Advantagene, Inc. Methods of cytotoxic gene therapy to treat tumors
US11090344B2 (en) 2016-05-27 2021-08-17 Dnatrix, Inc. Adenovirus and immunomodulator combination therapy
EP3534923A4 (en) * 2016-11-01 2020-05-27 DNAtrix, Inc. COMBINATION THERAPY FOR THE TREATMENT OF BRAIN CARCINOMAS
GB201804473D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy Modified oncolytic adenoviruses
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
EP4061405A1 (en) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
EP4175664A2 (en) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
CN114426945B (zh) * 2021-11-10 2024-08-23 西安交通大学医学院第一附属医院 胶质瘤类器官原代促活液、培养液及制备、培养方法
CN121335710A (zh) * 2023-04-07 2026-01-13 上海复诺健生物科技有限公司 重组溶瘤病毒与检查点抑制剂的组合用于治疗癌症

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2304281B1 (es) * 2006-02-01 2009-08-12 Dnatrix Inc. Adenovirus oncoliticos para el tratamiento del cancer.
BRPI0924123B8 (pt) 2008-12-22 2021-05-25 Oncos Therapeutics Oy vetores adenovirais oncolíticos, usos dos mesmos, composição farmacêutica e método para produzir gmcsf em uma célula in vitro
FI20090030A0 (fi) * 2009-02-02 2009-02-02 Akseli Eetu Hemminki Onkolyyttiset virukset
EA201590451A1 (ru) 2012-08-30 2016-05-31 Эмджен Инк. Способ лечения меланомы с применением вируса простого герпеса и ингибитора иммунной контрольной точки
US20150250837A1 (en) 2012-09-20 2015-09-10 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
US10350275B2 (en) 2013-09-21 2019-07-16 Advantagene, Inc. Methods of cytotoxic gene therapy to treat tumors
CN114317461A (zh) * 2013-11-22 2022-04-12 德那翠丝有限公司 表达免疫细胞刺激受体激动剂的腺病毒

Also Published As

Publication number Publication date
DK3293201T3 (da) 2020-12-07
EP3293201A1 (en) 2018-03-14
WO2018046803A1 (en) 2018-03-15
CN109715664A (zh) 2019-05-03
US20210121564A1 (en) 2021-04-29
HUE053236T2 (hu) 2021-06-28
JP2019532047A (ja) 2019-11-07
EP3783032A1 (en) 2021-02-24
US20190201525A1 (en) 2019-07-04
JP2022183170A (ja) 2022-12-08
US10940203B2 (en) 2021-03-09
AU2017324482A1 (en) 2019-04-11
PL3293201T3 (pl) 2021-06-14
US11690913B2 (en) 2023-07-04
SI3293201T1 (sl) 2021-03-31
JP7146739B2 (ja) 2022-10-04
PT3293201T (pt) 2020-12-07
HRP20210133T1 (hr) 2021-03-19
EP3293201B1 (en) 2020-11-04
ES2845690T3 (es) 2021-07-27

Similar Documents

Publication Publication Date Title
IL304820A (en) Preparations and methods for the treatment of cancer
SG11202001010UA (en) Methods and materials for assessing and treating cancer
IL267247B (en) Compositions and methods for treating cancer
IL267158B (en) Amino-triazopyridine compounds and their use in cancer treatment
IL266053A (en) Preparations and methods for the treatment of ezh2-mediated cancer
IL252610A0 (en) Methods and preparations for the treatment of cancer
HUE053236T2 (hu) Adenovírus és ellenõrzõpont-gátlók kombinálása rák kezelésére
LT3331915T (lt) Imuninio atsako kontrolinio taško inhibitoriai, skirti naudoti gydant kraujodaros prigimties vėžio formas
IL256523A (en) Compositions and methods for treating cancer
IL271019A (en) Tinostemustine for the treatment of ovarian cysts
EP3271483A4 (en) Methods and materials for assessing and treating cancer
SI3534885T1 (sl) Zaviralci farnezil-transferaze za uporabo pri zdravljenju raka
IL255638A (en) Compositions and methods for treating cancer
SG10202013112YA (en) Zinc-gamma-pga compositions and methods for treating cancer
IL261648A (en) Cinnolin-4-amine compounds and their use in treating cancer
IL259358A (en) Bis-pyridazine compounds and their use in treating cancer
IL274714A (en) Methods and materials for cancer assessment and treatment
EP3273970A4 (en) Methods and materials for treating cancer
ZA201802268B (en) Methods and compositions for preventing or treating cancer
IL255541A (en) Cabazitaxel and its use for treating cancer
PL3402889T3 (pl) Skojarzenie adenowirusa i środków chemioterapeutycznych do leczenia raka
GB201609402D0 (en) Materials and methods for treating cancer
SG10201912086QA (en) Compositions and methods for treating cancer
SMT202100667T1 (it) Metodi per trattare il cancro ovarico
HK40037008A (en) Methods and materials for assessing and treating cancer